logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.

    Article - En anglais

    Purpose 

    To examine the cost of incident cases of non-small-cell lung cancer (NSCLC) in a commercially insured cohort.

    Methods 

    Claims from Virginia Blue Cross and Blue Shield (BCBS) beneficiaries with lung cancer from 1989 to 1991 were merged with records from the Virginia Cancer Registry (VCR).

    Data from the VCR identified incident cases, stage, and type of cancer at diagnosis.

    Costs for all medical care included insurance payment, copayments, and deductibles for 2 years after diagnosis or until death.

    Results 

    Three hundred forty-nine incident NSCLC patients were evaluated.

    The mean 2-year cost for each patient after diagnosis or until death was $47,941 (95% confidence interval, $43,758 to $52,124).

    Total average costs and hospital days were significantly lower for local disease (537,514,21.2 days), but were similar for regional ($52,797,30.0 days) and distant ($49,382,33.0 days) disease.

    Hospital days accounted for 48% and hospital-based claims for 70% of costs.

    Initial treatments, which included radiation, unadjusted for stage, had the lowest survival rates and the highest costs, and were associated with the most hospital days.

    Initial stage, race, gender, and age were not predictors of total 2-year costs.

    The independent predictors of total 2-year costs were type of treatment any radiation therapy, any surgery, or any chemotherapy (all, P<. 001).

    Inpatient hospital days was only a modest predictor of costs after adjusting for type of treatment. (...)

    Mots-clés Pascal : Carcinome non petite cellule, Bronchopulmonaire, Etude cohorte, Analyse coût, Economie santé, Etats Unis, Amérique du Nord, Amérique, Compagnie assurance, Homme, Appareil respiratoire pathologie, Poumon pathologie, Bronche pathologie, Tumeur maligne

    Mots-clés Pascal anglais : Non small cell carcinoma, Bronchopulmonary, Cohort study, Cost analysis, Health economy, United States, North America, America, Insurance company, Human, Respiratory disease, Lung disease, Bronchus disease, Malignant tumor

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0234180

    Code Inist : 002B11A. Création : 11/09/1998.